An analysis of the relationship between metastases and cachexia in lung cancer patients

Masatoshi Shiono, Kan Huang, Robert J. Downey, Nikita Consul, Nicolas Villanueva, Kristen Beck, Kathleen Fenn, Donald Dietz, Takuhiro Yamaguchi, Shunsuke Kato, Chaitanya Divgi, Kevin Kalinsky, Ying Wei, Yuan Zhang, Alain C. Borczuk, Akira Inoue, Balazs Halmos, Swarnali Acharyya

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Weight loss and hematogenous metastases are poor prognosis factors in lung cancer patients that can but do not necessarily co-occur. We retrospectively investigated the clinical association between cachexia, tumor characteristics (such as metastatic burden and mutational status), and treatment in lung cancer patients. The medical records of 394 lung cancer patients from two institutions (Columbia University, USA and Tohoku University, Japan) were reviewed. Information collected included the presence of cachexia, histologic subtype, tumor stage, number of metastases, mutation status, treatment, and survival. Descriptive statistics were performed. Only stage IV patients exhibited >5% weight loss (0.8%, 2.2%, 3.6%, and 5.1%, for stages I to IV; P = 0.0001). Patients with metastases developed cachexia more often than patients without metastases independent of treatment (6.0% and 7.1% weight loss in patients with metastases vs. 2.5% and 2.0% in patients without metastases, before [P = 0.0001] and after [P < 0.0001] treatment, respectively). The change in number of metastatic sites over time correlated with increasing weight loss (5.2%, 10.6%, 13.4%, and 13.4%, for an increase of 0, 1, 2, and ≥3 metastatic sites, from initial diagnosis to the endpoint; P < 0.0001). Patients with cachexia had worse survival than patients without cachexia (hazard ratio, 2.94; 95% confidence interval, 2.08–4.16; P < 0.0001). Tumors with mutated KRAS were associated with an increased risk of weight loss (11.4% weight loss in patients with mutated KRAS vs. 6.0% in patients with wild-type KRAS; P = 0.0011). Our findings suggest that the capabilities of lung cancer to metastasize and cause cachexia might be linked intrinsically and are independent of treatments administered. KRAS-mutated tumors were more commonly associated with cachexia.

Original languageEnglish (US)
Pages (from-to)2641-2648
Number of pages8
JournalCancer Medicine
Volume5
Issue number9
DOIs
StatePublished - Sep 1 2016

Fingerprint

Cachexia
Lung Neoplasms
Neoplasm Metastasis
Weight Loss
Neoplasms
Therapeutics
Survival
Medical Records
Japan

Keywords

  • Cachexia
  • KRAS mutation
  • lung cancer
  • metastasis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Shiono, M., Huang, K., Downey, R. J., Consul, N., Villanueva, N., Beck, K., ... Acharyya, S. (2016). An analysis of the relationship between metastases and cachexia in lung cancer patients. Cancer Medicine, 5(9), 2641-2648. https://doi.org/10.1002/cam4.841

An analysis of the relationship between metastases and cachexia in lung cancer patients. / Shiono, Masatoshi; Huang, Kan; Downey, Robert J.; Consul, Nikita; Villanueva, Nicolas; Beck, Kristen; Fenn, Kathleen; Dietz, Donald; Yamaguchi, Takuhiro; Kato, Shunsuke; Divgi, Chaitanya; Kalinsky, Kevin; Wei, Ying; Zhang, Yuan; Borczuk, Alain C.; Inoue, Akira; Halmos, Balazs; Acharyya, Swarnali.

In: Cancer Medicine, Vol. 5, No. 9, 01.09.2016, p. 2641-2648.

Research output: Contribution to journalArticle

Shiono, M, Huang, K, Downey, RJ, Consul, N, Villanueva, N, Beck, K, Fenn, K, Dietz, D, Yamaguchi, T, Kato, S, Divgi, C, Kalinsky, K, Wei, Y, Zhang, Y, Borczuk, AC, Inoue, A, Halmos, B & Acharyya, S 2016, 'An analysis of the relationship between metastases and cachexia in lung cancer patients', Cancer Medicine, vol. 5, no. 9, pp. 2641-2648. https://doi.org/10.1002/cam4.841
Shiono M, Huang K, Downey RJ, Consul N, Villanueva N, Beck K et al. An analysis of the relationship between metastases and cachexia in lung cancer patients. Cancer Medicine. 2016 Sep 1;5(9):2641-2648. https://doi.org/10.1002/cam4.841
Shiono, Masatoshi ; Huang, Kan ; Downey, Robert J. ; Consul, Nikita ; Villanueva, Nicolas ; Beck, Kristen ; Fenn, Kathleen ; Dietz, Donald ; Yamaguchi, Takuhiro ; Kato, Shunsuke ; Divgi, Chaitanya ; Kalinsky, Kevin ; Wei, Ying ; Zhang, Yuan ; Borczuk, Alain C. ; Inoue, Akira ; Halmos, Balazs ; Acharyya, Swarnali. / An analysis of the relationship between metastases and cachexia in lung cancer patients. In: Cancer Medicine. 2016 ; Vol. 5, No. 9. pp. 2641-2648.
@article{bd45ff8139914b719b62837586a7e396,
title = "An analysis of the relationship between metastases and cachexia in lung cancer patients",
abstract = "Weight loss and hematogenous metastases are poor prognosis factors in lung cancer patients that can but do not necessarily co-occur. We retrospectively investigated the clinical association between cachexia, tumor characteristics (such as metastatic burden and mutational status), and treatment in lung cancer patients. The medical records of 394 lung cancer patients from two institutions (Columbia University, USA and Tohoku University, Japan) were reviewed. Information collected included the presence of cachexia, histologic subtype, tumor stage, number of metastases, mutation status, treatment, and survival. Descriptive statistics were performed. Only stage IV patients exhibited >5{\%} weight loss (0.8{\%}, 2.2{\%}, 3.6{\%}, and 5.1{\%}, for stages I to IV; P = 0.0001). Patients with metastases developed cachexia more often than patients without metastases independent of treatment (6.0{\%} and 7.1{\%} weight loss in patients with metastases vs. 2.5{\%} and 2.0{\%} in patients without metastases, before [P = 0.0001] and after [P < 0.0001] treatment, respectively). The change in number of metastatic sites over time correlated with increasing weight loss (5.2{\%}, 10.6{\%}, 13.4{\%}, and 13.4{\%}, for an increase of 0, 1, 2, and ≥3 metastatic sites, from initial diagnosis to the endpoint; P < 0.0001). Patients with cachexia had worse survival than patients without cachexia (hazard ratio, 2.94; 95{\%} confidence interval, 2.08–4.16; P < 0.0001). Tumors with mutated KRAS were associated with an increased risk of weight loss (11.4{\%} weight loss in patients with mutated KRAS vs. 6.0{\%} in patients with wild-type KRAS; P = 0.0011). Our findings suggest that the capabilities of lung cancer to metastasize and cause cachexia might be linked intrinsically and are independent of treatments administered. KRAS-mutated tumors were more commonly associated with cachexia.",
keywords = "Cachexia, KRAS mutation, lung cancer, metastasis",
author = "Masatoshi Shiono and Kan Huang and Downey, {Robert J.} and Nikita Consul and Nicolas Villanueva and Kristen Beck and Kathleen Fenn and Donald Dietz and Takuhiro Yamaguchi and Shunsuke Kato and Chaitanya Divgi and Kevin Kalinsky and Ying Wei and Yuan Zhang and Borczuk, {Alain C.} and Akira Inoue and Balazs Halmos and Swarnali Acharyya",
year = "2016",
month = "9",
day = "1",
doi = "10.1002/cam4.841",
language = "English (US)",
volume = "5",
pages = "2641--2648",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - An analysis of the relationship between metastases and cachexia in lung cancer patients

AU - Shiono, Masatoshi

AU - Huang, Kan

AU - Downey, Robert J.

AU - Consul, Nikita

AU - Villanueva, Nicolas

AU - Beck, Kristen

AU - Fenn, Kathleen

AU - Dietz, Donald

AU - Yamaguchi, Takuhiro

AU - Kato, Shunsuke

AU - Divgi, Chaitanya

AU - Kalinsky, Kevin

AU - Wei, Ying

AU - Zhang, Yuan

AU - Borczuk, Alain C.

AU - Inoue, Akira

AU - Halmos, Balazs

AU - Acharyya, Swarnali

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Weight loss and hematogenous metastases are poor prognosis factors in lung cancer patients that can but do not necessarily co-occur. We retrospectively investigated the clinical association between cachexia, tumor characteristics (such as metastatic burden and mutational status), and treatment in lung cancer patients. The medical records of 394 lung cancer patients from two institutions (Columbia University, USA and Tohoku University, Japan) were reviewed. Information collected included the presence of cachexia, histologic subtype, tumor stage, number of metastases, mutation status, treatment, and survival. Descriptive statistics were performed. Only stage IV patients exhibited >5% weight loss (0.8%, 2.2%, 3.6%, and 5.1%, for stages I to IV; P = 0.0001). Patients with metastases developed cachexia more often than patients without metastases independent of treatment (6.0% and 7.1% weight loss in patients with metastases vs. 2.5% and 2.0% in patients without metastases, before [P = 0.0001] and after [P < 0.0001] treatment, respectively). The change in number of metastatic sites over time correlated with increasing weight loss (5.2%, 10.6%, 13.4%, and 13.4%, for an increase of 0, 1, 2, and ≥3 metastatic sites, from initial diagnosis to the endpoint; P < 0.0001). Patients with cachexia had worse survival than patients without cachexia (hazard ratio, 2.94; 95% confidence interval, 2.08–4.16; P < 0.0001). Tumors with mutated KRAS were associated with an increased risk of weight loss (11.4% weight loss in patients with mutated KRAS vs. 6.0% in patients with wild-type KRAS; P = 0.0011). Our findings suggest that the capabilities of lung cancer to metastasize and cause cachexia might be linked intrinsically and are independent of treatments administered. KRAS-mutated tumors were more commonly associated with cachexia.

AB - Weight loss and hematogenous metastases are poor prognosis factors in lung cancer patients that can but do not necessarily co-occur. We retrospectively investigated the clinical association between cachexia, tumor characteristics (such as metastatic burden and mutational status), and treatment in lung cancer patients. The medical records of 394 lung cancer patients from two institutions (Columbia University, USA and Tohoku University, Japan) were reviewed. Information collected included the presence of cachexia, histologic subtype, tumor stage, number of metastases, mutation status, treatment, and survival. Descriptive statistics were performed. Only stage IV patients exhibited >5% weight loss (0.8%, 2.2%, 3.6%, and 5.1%, for stages I to IV; P = 0.0001). Patients with metastases developed cachexia more often than patients without metastases independent of treatment (6.0% and 7.1% weight loss in patients with metastases vs. 2.5% and 2.0% in patients without metastases, before [P = 0.0001] and after [P < 0.0001] treatment, respectively). The change in number of metastatic sites over time correlated with increasing weight loss (5.2%, 10.6%, 13.4%, and 13.4%, for an increase of 0, 1, 2, and ≥3 metastatic sites, from initial diagnosis to the endpoint; P < 0.0001). Patients with cachexia had worse survival than patients without cachexia (hazard ratio, 2.94; 95% confidence interval, 2.08–4.16; P < 0.0001). Tumors with mutated KRAS were associated with an increased risk of weight loss (11.4% weight loss in patients with mutated KRAS vs. 6.0% in patients with wild-type KRAS; P = 0.0011). Our findings suggest that the capabilities of lung cancer to metastasize and cause cachexia might be linked intrinsically and are independent of treatments administered. KRAS-mutated tumors were more commonly associated with cachexia.

KW - Cachexia

KW - KRAS mutation

KW - lung cancer

KW - metastasis

UR - http://www.scopus.com/inward/record.url?scp=84991105228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991105228&partnerID=8YFLogxK

U2 - 10.1002/cam4.841

DO - 10.1002/cam4.841

M3 - Article

VL - 5

SP - 2641

EP - 2648

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 9

ER -